It was 2013, and the launch of Johnson & Johnson’s drug Invokana ushered in a new class of type 2 diabetes medications...
Pitocin, made by New Jersey-based JHP Pharmaceuticals, is a synthetic form of the natural hormone oxytocin that regulates uterine contractions.
Fortunately, American consumers have never had greater access to the civil justice system and the right to seek compensation when harmed by dangerous products. And, with thousands of prescription drugs and medical devices on the market, patients have never faced more harm from side effects.
Coming off a 2016 that saw just over 20 new drugs approved for launch by the FDA, 2017 was a marked improvement - and 2018 looks to be no different. Experts are predicting several of the medications slated for launch next year could become household names.
Cerebral palsy is a debilitating condition that affects the areas of the brain controlling muscle function and body movement. New cases are diagnosed in nearly 10,000 children each year, and around half a million people live with the condition in the United States.
In June, details emerged that DePuy’s Attune knee implant system, one of the most popular on the market, was experiencing higher-than-expected failure rates among patients.
Last week, it emerged Johnson & Johnson’s Janssen unit has asked the FDA to approve expanded uses of its diabetes drug Invokana (canagliflozin), to include reducing the risk of major cardiovascular injuries and death in those with diabetes.
With the ink barely dry on last month’s $417 million award to a California woman who developed ovarian cancer after decades of using Johnson & Johnson’s baby powder products, many are asking if they should join the litigation, and what this could mean for their case.